{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T01:16:39Z","timestamp":1783127799190,"version":"3.54.6"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000042","name":"Amgen Foundation Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016399","name":"URCA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019899","name":"Aviesan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019899","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.rmr.2026.04.002","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T20:20:09Z","timestamp":1778271609000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["R\u00e9sistance \u00e0 l\u2019immunoth\u00e9rapie dans le CBNPC\u00a0:\u00a0\u00e9tat des connaissances actuelles"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3128-9348","authenticated-orcid":false,"given":"J.","family":"Ancel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dewolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Nawrocki-Raby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Durlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Dalstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cortot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Dormoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gilles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Polette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Desl\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2026.04.002_bib0485","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36\u00a0cancers in 185\u00a0countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J Clinicians"},{"key":"10.1016\/j.rmr.2026.04.002_bib0490","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1158\/1055-9965.EPI-19-0221","article-title":"Cancer progress and priorities: lung cancer","volume":"28","author":"Schabath","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.rmr.2026.04.002_bib0495","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.rmr.2026.04.002_bib0500","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","article-title":"Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends","volume":"8","author":"Sun","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.rmr.2026.04.002_bib0505","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3\u00a0KEYNOTE-189\u00a0Study","volume":"41","author":"Garassino","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.rmr.2026.04.002_bib0510","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407\u00a0Study","volume":"41","author":"Novello","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.rmr.2026.04.002_bib0515","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC Trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2026.04.002_bib0520","doi-asserted-by":"crossref","first-page":"103464","DOI":"10.1016\/j.esmoop.2024.103464","article-title":"Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R","volume":"9","author":"Filippi","year":"2024","journal-title":"ESMO Open"},{"issue":"21","key":"10.1016\/j.rmr.2026.04.002_bib0525","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"issue":"Suppl. 17","key":"10.1016\/j.rmr.2026.04.002_bib0530","doi-asserted-by":"crossref","first-page":"LBA8010","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8010","article-title":"Neoadjuvant nivolumab (NIVO)+chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816","volume":"42","author":"Spicer","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.rmr.2026.04.002_bib0535","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1\u00a0of at least 50\u00a0%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2026.04.002_bib0540","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.jtho.2021.01.272","article-title":"OA01.03\u00a0Clinical benefits of first-line (1l) cemiplimab monotherapy by PD-l1\u00a0expression levels in patients with advanced NSCLC","volume":"16","author":"Kilickap","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2026.04.002_bib0545","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.rmr.2026.04.002_bib0550","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.rmr.2026.04.002_bib0555","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-021-00431-4","article-title":"Programmed death ligand 1\u00a0signals in cancer cells","volume":"22","author":"Kornepati","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.rmr.2026.04.002_bib0560","first-page":"28","article-title":"CD80-Fc fusion protein as a potential cancer immunotherapy strategy","volume":"7","author":"Wang","year":"2024","journal-title":"Antib Ther"},{"key":"10.1016\/j.rmr.2026.04.002_bib0565","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12964-023-01264-4","article-title":"Integrin signaling in cancer: bidirectional mechanisms and therapeutic opportunities","volume":"21","author":"Li","year":"2023","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.rmr.2026.04.002_bib0570","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.cell.2015.08.052","article-title":"Melanoma cell-intrinsic PD-1\u00a0receptor functions promote tumor growth","volume":"162","author":"Kleffel","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.rmr.2026.04.002_bib0575","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.celrep.2017.07.075","article-title":"PDL1\u00a0signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity","volume":"20","author":"Gato-Ca\u00f1as","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.rmr.2026.04.002_bib0580","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1182\/blood-2007-11-123141","article-title":"B7-H1\u00a0is a ubiquitous antiapoptotic receptor on cancer cells","volume":"111","author":"Azuma","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.rmr.2026.04.002_bib0585","doi-asserted-by":"crossref","first-page":"14572","DOI":"10.1038\/ncomms14572","article-title":"Tumour and host cell PD-L1\u00a0is required to mediate suppression of anti-tumour immunity in mice","volume":"8","author":"Lau","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.rmr.2026.04.002_bib0590","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.molcel.2019.04.005","article-title":"PD-L1 (B7-H1) competes with the RNA exosome to regulate the DNA damage response and can be targeted to sensitize to radiation or chemotherapy","volume":"74","author":"Tu","year":"2019","journal-title":"Mol Cell"},{"key":"10.1016\/j.rmr.2026.04.002_bib0595","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2026.04.002_bib0600","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3\u00a0trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2026.04.002_bib0605","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2026.04.002_bib0610","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The Challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.rmr.2026.04.002_bib0615","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1\u00a0inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2026.04.002_bib0620","doi-asserted-by":"crossref","DOI":"10.1038\/s43018-024-00752-x","article-title":"Tissue-specific thresholds of mutation burden associated with anti-PD-1\/L1\u00a0therapy benefit and prognosis in microsatellite-stable cancers","author":"Muquith","year":"2024","journal-title":"Nat Cancer [Internet]"},{"key":"10.1016\/j.rmr.2026.04.002_bib0625","doi-asserted-by":"crossref","first-page":"100124","DOI":"10.1016\/j.esmoop.2021.100124","article-title":"The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials","volume":"6","author":"Galvano","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.rmr.2026.04.002_bib0630","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jmoldx.2024.05.002","article-title":"Recommendations for tumor mutational burden assay validation and reporting: a Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, and Society for Immunotherapy of Cancer","volume":"26","author":"Furtado","year":"2024","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.rmr.2026.04.002_bib0635","doi-asserted-by":"crossref","first-page":"e0242173","DOI":"10.1371\/journal.pone.0242173","article-title":"Prognostic value of the common tumour-infiltrating lymphocyte subtypes for patients with non-small cell lung cancer: a meta-analysis","volume":"15","author":"Chen","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.rmr.2026.04.002_bib0640","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10\u00a0challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.rmr.2026.04.002_bib0645","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1158\/1078-0432.CCR-23-4027","article-title":"Combining genomic biomarkers to guide immunotherapy in non-small cell lung cancer","volume":"30","author":"van de\u00a0Haar","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rmr.2026.04.002_bib0650","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","article-title":"Diminished Efficacy of Programmed Death-(Ligand)1\u00a0Inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status","volume":"17","author":"Ricciuti","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2026.04.002_bib0655","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41586-024-07943-7","article-title":"CTLA4\u00a0blockade abrogates KEAP1\/STK11-related resistance to PD-(L)1\u00a0inhibitors","volume":"635","author":"Skoulidis","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.rmr.2026.04.002_bib0660","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/s41416-020-0834-6","article-title":"Emerging role of PTEN loss in evasion of the immune response to tumours","volume":"122","author":"Vidotto","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.rmr.2026.04.002_bib0665","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN promotes resistance to T cell-mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.rmr.2026.04.002_bib0670","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41577-018-0029-z","article-title":"IFN\u03b3: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy","volume":"18","author":"Ivashkiv","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.rmr.2026.04.002_bib0675","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41467-023-35948-9","article-title":"IFN\u03b3 signaling in cytotoxic T cells restricts anti-tumor responses by inhibiting the maintenance and diversity of intra-tumoral stem-like T cells","volume":"14","author":"Mazet","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.rmr.2026.04.002_bib0680","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41568-019-0109-9","article-title":"Epigenetic therapy in immune-oncology","volume":"19","author":"Jones","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.rmr.2026.04.002_bib0685","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1158\/1078-0432.CCR-22-0784","article-title":"The crossroads of cancer epigenetics and immune checkpoint therapy","volume":"29","author":"Micevic","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rmr.2026.04.002_bib0690","doi-asserted-by":"crossref","first-page":"875149","DOI":"10.3389\/fphar.2022.875149","article-title":"TCR coexpression signature predicts immunotherapy resistance in NSCLC","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.rmr.2026.04.002_bib0695","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2326-6066.CIR-19-0398","article-title":"TCR repertoire diversity of peripheral PD-1+CD8+T cells predicts clinical outcomes after immunotherapy in patients with non-small cell lung cancer","volume":"8","author":"Han","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.rmr.2026.04.002_bib0700","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41698-024-00781-w","article-title":"Diversity of TCR repertoire predicts recurrence after CRT followed by durvalumab in patients with NSCLC","volume":"9","author":"Shirasawa","year":"2025","journal-title":"Precis Onc"},{"key":"10.1016\/j.rmr.2026.04.002_bib0705","doi-asserted-by":"crossref","first-page":"E3729","DOI":"10.3390\/cancers12123729","article-title":"Primary and acquired resistance to immunotherapy in lung cancer: unveiling the mechanisms underlying of immune checkpoint blockade therapy","volume":"12","author":"Boyero","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.rmr.2026.04.002_bib0710","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","article-title":"Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer","volume":"42","author":"Memon","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.rmr.2026.04.002_bib0715","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1038\/s41467-023-40745-5","article-title":"Acquired resistance to anti-PD1\u00a0therapy in patients with NSCLC associates with immunosuppressive T cell phenotype","volume":"14","author":"Hiltbrunner","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.rmr.2026.04.002_bib0720","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.rmr.2026.04.002_bib0725","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/j.cell.2022.03.033","article-title":"Quiescent cancer cells resist T\u00a0cell attack by forming an immunosuppressive niche","volume":"185","author":"Baldominos","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.rmr.2026.04.002_bib0730","doi-asserted-by":"crossref","first-page":"715234","DOI":"10.3389\/fimmu.2021.715234","article-title":"CD8+ T cell exhaustion in cancer","volume":"12","author":"Dolina","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.rmr.2026.04.002_bib0735","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.rmr.2026.04.002_bib0740","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1200\/JCO.23.00580","article-title":"Genomic and immunophenotypic landscape of acquired resistance to PD-(L)1\u00a0blockade in non-small-cell lung cancer","volume":"42","author":"Ricciuti","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.rmr.2026.04.002_bib0745","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2174\/1568009622666220307105107","article-title":"Mesenchymal Epithelial Transition (MET): a key player in chemotherapy resistance and an emerging target for potentiating cancer immunotherapy","volume":"22","author":"To","year":"2022","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.rmr.2026.04.002_bib0750","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000510103","article-title":"Clinical impact of the epithelial-mesenchymal transition in lung cancer as a biomarker assisting in therapeutic decisions","volume":"211","author":"Ancel","year":"2022","journal-title":"Cells Tissues Organs"},{"key":"10.1016\/j.rmr.2026.04.002_bib0755","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cytogfr.2017.05.008","article-title":"Deciphering the loop of epithelial-mesenchymal transition, inflammatory cytokines and cancer immunoediting","volume":"36","author":"Sistigu","year":"2017","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.rmr.2026.04.002_bib0760","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/s12967-025-06422-5","article-title":"Epithelial-mesenchymal transition orchestrates tumor microenvironment: current perceptions and challenges","volume":"23","author":"Xie","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.rmr.2026.04.002_bib0765","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.3390\/cancers11101411","article-title":"Programmed death-ligand 1\u00a0and vimentin: a tandem marker as prognostic factor in NSCLC","volume":"11","author":"Ancel","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.rmr.2026.04.002_bib0770","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.3390\/cancers12061632","article-title":"EMT-associated heterogeneity in circulating tumor cells: sticky friends on the road to metastasis","volume":"12","author":"Genna","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.rmr.2026.04.002_bib0775","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd1616","article-title":"Overcoming microenvironmental resistance to PD-1\u00a0blockade in genetically engineered lung cancer models","volume":"13","author":"Martinez-Usatorre","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.rmr.2026.04.002_bib0780","first-page":"252","article-title":"A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy","volume":"3","author":"Fujiwara","year":"2020","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.rmr.2026.04.002_bib0785","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1186\/s12964-024-01711-w","article-title":"Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance","volume":"22","author":"Yang","year":"2024","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.rmr.2026.04.002_bib0790","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.3390\/cancers16162919","article-title":"Overcoming resistance to checkpoint inhibitors with combination strategies in the treatment of non-small cell lung cancer","volume":"16","author":"Reyes","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.rmr.2026.04.002_bib0795","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2020.02.022","article-title":"Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: results of the IFCT-1103\u00a0ULTIMATE study","volume":"131","author":"Cortot","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.rmr.2026.04.002_bib0800","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/1750743X.2025.2536454","article-title":"Overcoming immunotherapy resistance in non-small cell lung cancer: a narrative review of related factors","volume":"17","author":"Guti\u00e9rrez-Babativa","year":"2025","journal-title":"Immunotherapy"},{"key":"10.1016\/j.rmr.2026.04.002_bib0805","doi-asserted-by":"crossref","first-page":"v658","DOI":"10.1093\/annonc\/mdz260.113","volume":"30","author":"Zalcman","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.rmr.2026.04.002_bib0810","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.3390\/cancers15133499","article-title":"Double guard efficiency and safety-overcoming resistance to immunotherapy by blocking or stimulating several immune checkpoints in non-small cell lung cancer patients","volume":"15","author":"Kalinka","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.rmr.2026.04.002_bib0815","doi-asserted-by":"crossref","first-page":"10027","DOI":"10.1007\/s00432-023-04919-4","article-title":"To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations","volume":"149","author":"Cai","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.rmr.2026.04.002_bib0820","doi-asserted-by":"crossref","DOI":"10.20517\/cdr.2025.14","article-title":"Tumor microenvironment-driven resistance to immunotherapy in non-small cell lung cancer: strategies for cold-to-hot tumor transformation","author":"Yu","year":"2025","journal-title":"Cancer Drug Resist [Internet]"},{"key":"10.1016\/j.rmr.2026.04.002_bib0825","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12943-020-01260-z","article-title":"Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook","volume":"19","author":"Horvath","year":"2020","journal-title":"Mol Cancer"},{"key":"10.1016\/j.rmr.2026.04.002_bib0830","doi-asserted-by":"crossref","first-page":"7347","DOI":"10.2147\/OTT.S214211","article-title":"OX40 (CD134) and OX40\u00a0ligand, important immune checkpoints in cancer","volume":"12","author":"Deng","year":"2019","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.rmr.2026.04.002_bib0835","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s12276-023-01136-4","article-title":"4-1BB immunotherapy: advances and hurdles","volume":"56","author":"Singh","year":"2024","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.rmr.2026.04.002_bib0840","doi-asserted-by":"crossref","first-page":"e172728","DOI":"10.1172\/jci.insight.172728","article-title":"Overcoming lung cancer immunotherapy resistance by combining nontoxic variants of IL-12\u00a0and IL-2","volume":"8","author":"Horton","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.rmr.2026.04.002_bib0845","doi-asserted-by":"crossref","first-page":"11548","DOI":"10.3390\/cimb46100686","article-title":"Interleukin-12\u00a0delivery strategies and advances in tumor immunotherapy","volume":"46","author":"Dong","year":"2024","journal-title":"CIMB"},{"key":"10.1016\/j.rmr.2026.04.002_bib0850","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.semcancer.2022.06.010","article-title":"Chemokines and NSCLC: emerging role in prognosis, heterogeneity, and therapeutics","volume":"86","author":"Srivastava","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.rmr.2026.04.002_bib0855","doi-asserted-by":"crossref","first-page":"e000433","DOI":"10.1136\/jitc-2019-000433","article-title":"Dual targeting of TGF-\u03b2 and PD-L1\u00a0via a bifunctional anti-PD-L1\/TGF-\u03b2RII agent: status of preclinical and clinical advances","volume":"8","author":"Lind","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.rmr.2026.04.002_bib0860","doi-asserted-by":"crossref","first-page":"1212209","DOI":"10.3389\/fimmu.2023.1212209","article-title":"Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy","volume":"14","author":"Kurago","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.rmr.2026.04.002_bib0865","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1021\/acsptsci.5c00057","article-title":"Insights from clinical trials on A2A adenosine receptor antagonists for cancer treatment","volume":"8","author":"Deb","year":"2025","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.rmr.2026.04.002_bib0870","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00011-023-01833-w","article-title":"Identification and validation of the association of Janus kinase 2\u00a0mutations with the response to immune checkpoint inhibitor therapy","volume":"73","author":"Chen","year":"2024","journal-title":"Inflamm Res"},{"key":"10.1016\/j.rmr.2026.04.002_bib0875","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.3390\/biomedicines13092160","article-title":"STING-activating nanoparticles combined with PD-1\/PD-L1\u00a0blockade: a synergistic approach in cancer immunotherapy","volume":"13","author":"Bartusik-Aebisher","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.rmr.2026.04.002_bib0880","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1158\/1078-0432.CCR-24-3630","article-title":"Phase I and II clinical studies of the STING agonist ulevostinag with and without pembrolizumab in participants with advanced or metastatic solid tumors or lymphomas","volume":"31","author":"Harrington","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rmr.2026.04.002_bib0885","doi-asserted-by":"crossref","first-page":"e010511","DOI":"10.1136\/jitc-2024-010511","article-title":"Phase I dose-escalation and pharmacodynamic study of STING agonist E7766\u00a0in advanced solid tumors","volume":"13","author":"Luke","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.rmr.2026.04.002_bib0890","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","article-title":"Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1\u00a0trial","volume":"27","author":"Creelan","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.rmr.2026.04.002_bib0895","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.cllc.2022.07.009","article-title":"A phase IB trial of autologous cytokine-induced killer cells in combination with sintilimab, monoclonal antibody against programmed cell death-1, plus chemotherapy in patients with advanced non-small-cell lung cancer","volume":"23","author":"Zhou","year":"2022","journal-title":"Clinical Lung Cancer"},{"key":"10.1016\/j.rmr.2026.04.002_bib0900","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/ijc.35422","article-title":"Efficacy and safety of autologous CIK cell therapy plus Toripalimab with or without chemotherapy in advanced NSCLC: a phase II study","volume":"157","author":"Zhong","year":"2025","journal-title":"Int J Cancer"},{"key":"10.1016\/j.rmr.2026.04.002_bib0905","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.annonc.2023.07.006","article-title":"Randomized open-label controlled study of cancer vaccine OSE2101\u00a0versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1","volume":"34","author":"Besse","year":"2023","journal-title":"Ann Oncol"},{"issue":"Suppl.\u00a016","key":"10.1016\/j.rmr.2026.04.002_bib0910","article-title":"Phase 3\u00a0trial of the therapeutic cancer vaccine OSE2101\u00a0versus docetaxel in patients with metastatic non-small cell lung cancer and secondary resistance to immunotherapy","volume":"43","author":"Liu","year":"2025","journal-title":"JCO [Internet]"},{"key":"10.1016\/j.rmr.2026.04.002_bib0915","doi-asserted-by":"crossref","first-page":"102220","DOI":"10.1016\/j.esmoop.2023.102220","article-title":"Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis","volume":"9","author":"Landr\u00e9","year":"2024","journal-title":"ESMO Open"},{"issue":"Suppl. 16","key":"10.1016\/j.rmr.2026.04.002_bib0920","doi-asserted-by":"crossref","first-page":"8516","DOI":"10.1200\/JCO.2025.43.16_suppl.8516","article-title":"Randomized trial of relevance of time-of-day of immunochemotherapy for progression-free and overall survival in patients with non-small cell lung cancer","volume":"43","author":"Zhang","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.rmr.2026.04.002_bib0925","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2026.04.002_bib0930","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non\u2013small-cell lung cancer with PD-L1\u00a0tumor proportion score of 50\u00a0% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.rmr.2026.04.002_bib0935","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1\u2013SElected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2026.04.002_bib0940","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(23)00329-7","article-title":"First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50\u00a0% or more (EMPOWER-Lung 1): 35-month follow-up from a multicentre, open-label, randomised, phase 3\u00a0trial","volume":"24","author":"\u00d6zg\u00fcro\u011flu","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rmr.2026.04.002_bib0945","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jtho.2020.03.028","article-title":"Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial","volume":"15","author":"Jotte","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2026.04.002_bib0950","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3\u00a0IMpower132\u00a0Trial","volume":"16","author":"Nishio","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2026.04.002_bib0955","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.jtho.2021.07.015","article-title":"Updated overall survival data and predictive biomarkers of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3\u00a0ORIENT-11\u00a0Study","volume":"16","author":"Yang","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2026.04.002_bib0960","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.jtho.2021.04.011","article-title":"Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase 3\u00a0trial (ORIENT-12)","volume":"16","author":"Zhou","year":"2021","journal-title":"J Thorac Oncol"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842526000100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842526000100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:25:34Z","timestamp":1783124734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842526000100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":96,"alternative-id":["S0761842526000100"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2026.04.002","relation":{},"ISSN":["0761-8425"],"issn-type":[{"value":"0761-8425","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"R\u00e9sistance \u00e0 l\u2019immunoth\u00e9rapie dans le CBNPC\u00a0:\u00a0\u00e9tat des connaissances actuelles","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2026.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 SPLF. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}